Therefore, targeting CBX1 simultaneously inhibits tumorigenesis and disrupts the immunosuppressive phenotype in NPC, which may synergize with PD‐L1/PD‐1 blockade, considering the unsatisfactory response rate for immunotherapy in NPC.[3] Nevertheless, we acknowledge the limitation that in the present study we examined the immunomodulatory effects of CBX1 in vivo using the MC38 immune model due to the lack of murine NPC cells. The gene discussed is CBX1; the disease is nasopharyngeal carcinoma.